The L’Oreal Groupe intends to increase its equity investment in the Galderma Group by 10%. This makes its total investment 20%.

L’Oreal has acquired this additional 10% from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers).

Flemming Ørnskov, Chief Executive Officer of Galderma, said,

“With strengthened commercial execution, continued platform and portfolio expansion, and an increasingly consumer-focused approach to innovation, we are rapidly scaling into a dermatology powerhouse. We are pleased with L’Oréal’s increased investment, which affirms our direction and the meaningful value creation we expect in the years ahead. As we move into 2026, we remain fully focused on our Integrated Dermatology Strategy and on serving our customers, consumers, and patients.”  

In addition to this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal. They will replace the board members representing the consortium led by EQT at the 2026 Annual General Meeting. 

Also, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. 

This ongoing collaboration brings together Galderma’s scientific leadership in dermatology and L’Oréal’s expertise as the world’s leading beauty player. 

With a shared focus on skincare and skin health, innovation, and long-term growth, Galderma and L’Oréal are well-positioned in the fast-growing, consumer-focused dermatology and beauty markets.